Core Viewpoint - The stock of Baixinan-B (02185) has seen a significant increase, with a rise of over 14% during trading, currently reported at 8.70 HKD, with a trading volume of 109 million HKD. This surge is attributed to positive developments in the renal denervation (RDN) market, particularly following Boston Scientific's acquisition of SoniVie for 600 million USD and updates to hypertension treatment guidelines by major American health organizations [1]. Company Summary - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage in the market [1]. - The company has established strategic partnerships with Yuan Da Health and other international entities, which are expected to accelerate its commercialization efforts [1]. Industry Summary - The RDN procedure is emerging as a new therapeutic approach for uncontrolled and resistant hypertension, with a projected market size in China exceeding 10 billion RMB by 2032, according to Frost & Sullivan [1]. - Recent updates from the American College of Cardiology and the American Heart Association have included RDN in their IIb level recommendations for hypertension treatment, indicating a growing acceptance and potential for clinical application [1]. - The proposed national coverage decision by the Centers for Medicare & Medicaid Services (CMS) in the U.S. is expected to significantly expedite the clinical promotion and application of RDN if approved [1].

该行指出，经皮去肾交感神经术（RDN）是针对未控及顽固高血压器械新疗法。根据灼识咨询，预计 2032 年中国 RDN 年市场规模超过 100 亿元人民币。该行指出，百心安 Iberis RDN 系统是全球唯一获批 上市能兼具经桡动脉（TRA）和经股动脉双入路 RDN，先发优势显著，国内已与远大健康、海外多国 家地区联合蓝帆柏盛达成重磅战略合作；德国、法国已将 Iberis RDN 纳入医保，当前正为百心安商业 化加速起点。 华福证券发布研报称，2025年3月波士顿科学以总价6亿美元收购SoniVie积极入局RDN赛道；8月美国心 脏病学会和美国心脏协会更新高血压治疗指南并将RDN纳入指南IIb级推荐；美国医保(CMS)7月发布的 RDN国家覆盖决定拟议稿，后续若通过，临床推广应用将大幅提速。 智通财经APP获悉，百心安-B(02185)再涨超10%，截至发稿，涨13.5%，报8.83港元，成交额1.06亿港 元。 ...